• My Trial Guide

    My Trial Guide

    Using this powerful database, and based on the genetic mutation of your tumor, you can access specific clinical trials, find out about personalized treatment options, learn more about your cancer, and talk with a Mass General Cancer Center expert.

    Click here to begin working with My Trial Guide »
    Linnea Duff

How to Get Tested

Getting tested is the first step in finding out what Targeted Therapy could work for you.

Find Clinical Trials

My Trial Guide will help you identify gene-based clinical trials of targeted therapies that may be just right for you.

Set Up a Consultation

The Mass General Cancer Center has world-renowned experts who are ready to help you. You're not in this alone.

  • Clinical Trials
  • Recent Advances
  • Patient Stories
  • Next Steps
  • Our Team

 

The Mass General Cancer Center’s gene-based cancer website can help you access important information about clinical trials that are designed to fight specific cancer mutations, as well as providing critical information regarding these mutations. Use our exclusive My Trial Guide tool to guide you to the best clinical trial and personalized treatment options for you.

Search by Disease, Gene, Mutation, or Drug »

Mutated IDH1 identifies brain tumors that benefit from aggressive surgery

February 3,2014

A team led by investigators from the Massachusetts General Hospital have found that patients with malignant astrocytoma – the most common malignant brain tumor – whose tumors carry a mutation in the IDH1 gene benefit greatly from surgical removal of the largest possible amount of tumor. read more »

Multi-institutional team finds targetable BRAF mutations in rare brain tumor

January 12, 2014

A team led by investigators from MGH, Brigham and Women's Hospital and the Broad Institute has found that a gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma. Their discovery, reported online in Nature Genetics, could lead to new therapies for this currently hard-to-treat tumor. read more »

U. S. Food and Drug Administration accelerated approval to trametinib and dabrafenib

January 1, 2014

The U. S. Food and Drug Administration granted accelerated approval to trametinib (Mekinist tablets, GlaxoSmithKline, LLC) and dabrafenib (Tafinlar capsules, GlaxoSmithKline, LLC) for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. read more »

U. S. Food and Drug Administration approved afatinib

July 12, 2013

On July 12, 2013, the U. S. Food and Drug Administration approved afatinib (Gilotrif tablets, Boehringer Ingelheim Pharmaceuticals, Inc.), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. read more »

MGH-led crizotinib studies shed new light on targeted lung cancer therapy

June 3, 2013

Research teams led by Massachusetts General Hospital (MGH) Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specific genetic mutations. read more »

U. S. Food and Drug Administration approved dabrafenib

May 29, 2013

On May 29, 2013, the U. S. Food and Drug Administration (FDA) approved dabrafenib (TAFINLAR capsule, GlaxoSmithKline, LLC), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. read more »

U. S. Food and Drug Administration approved trametinib

May 29, 2013

On May 29, 2013, the U. S. Food and Drug Administration approved trametinib (MEKINIST tablet, GlaxoSmithKline, LLC), for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation as detected by an FDA-approved test. Concurrent with this approval, FDA approved the THxID BRAF assay (bioMerieux, Inc.) for detection of BRAF V600E and V600K mutations. read more »

MGH-led study of dabrafenib and trametinib named among Clinical Research Forum's Top 10 Clinical Research Achievements of 2012

September 29, 2012

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma. read more »

U. S. Food and Drug Administration approved erlotinib

May 14, 2013

On May 14, 2013, the U. S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc.) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. read more »

Next-generation PI3 Kinase Inhibitor Demonstrated Early Efficacy, Safety

April 7, 2013

GDC-0032, a potent, next-generation PI3 kinase inhibitor, demonstrated early signs of efficacy for patients with cancers driven by mutations in the PI3 kinase alpha gene, according to first in-human results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. read more »

U. S. Food and Drug Administration approved regorafenib

February 25, 2013

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease. read more »

BRAF inhibitor treatment causes melanoma cells to shift how they produce energy

March 8, 2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings suggest a strategy to improve the effectiveness of currently available targeted therapies. read more »

Transition in cell type parallels treatment response, disease progression in breast cancer

January 31, 2013

A process that normally occurs in developing embryos – the changing of one basic cell type into another – has also been suspected of playing a role in cancer metastasis. Now a study from MGH Cancer Center researchers has associated this process, called epithelial-mesenchymal transition, with disease progression and treatment response in breast cancer patients. read more »

Cancer Center team identifies potential treatment target for KRAS

Feb 16, 2012

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have identified a new potential strategy for treating colon tumors driven by mutations in the KRAS gene, which usually resist both conventional and targeted treatments. read more »

First credible treatment option for metastatic melanoma

August 26, 2010

One targeted cancer therapy nearing clinical application illustrates why patients and their families have new hope as a result of such therapies. Scientists have known for some time that the most commonly mutated gene in melanoma – a leading cause of death in young adults – is called BRAF. However, efforts to disable this mutation... read more »

Combination of targeted drugs delays resistance in melanoma patients

October 01, 2012

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF... read more »

Mass. General study defines a new genetic subtype of lung cancer

January 31, 2012

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer... read more »

New lung cancer pill highlights improved way of treating patients

Aug. 30, 2011

A new drug to combat a certain type of lung cancer is being hailed today as an "amazing development" by medical experts. The drug crizotinib (Xalkori), manufactured by Pfizer and approved last week by the Food and Drug Administration, is intended... read more »

Novel gene mutations associated with bile duct cancer

January 18, 2012

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited... read more »

The path to personalized treatment

March 28, 2012

In the largest study of its kind, researchers have profiled genetic changes in cancer with drug sensitivity in order to develop a personalized approach to cancer treatments. read more »

Greg Vrettos

Athletic. Healthy eater. Non-smoker. At 57, Greg Vrettos' lifestyle profile read like every doctor's recommendation for good health. read more »

Linnea Duff

When Linnea Duff, an active 46-year old mother of three, began experiencing shortness of breath... read more »

Speak with an access nurse today. Our access nurses will help direct you toward the right resources for your needs. Call 877-789-6100
Clinical Trials
The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Learn More »

Contact Us
Please fill out the "Request a Consultation" form or call to get in touch with the MGH Cancer Center today.Ask »

Frequently Asked Questions
Learn more about clinical trials, genomic tests and more.
Explore »

Daniel A. Haber, MD, PhD

Dr. Daniel Haber is Director of Massachusetts General Hospital (MGH) Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School. He received his MD and PhD degrees at Stanford... read more »

David Ryan, MD

On Oct. 12, the Department of Medicine and the Cancer Center announced the appointment of David Ryan, MD, as the new chief of Hematology/Oncology at the MGH. Ryan, who succeeds Jose Baselga, MD, PhD, joined the MGH Cancer Center in 1998. read more »

Keith Flaherty, MD

Dr. Flaherty is director of Developmental Therapies at the Massachusetts General Hospital Cancer Center. Dr. Flaherty’s research and clinical focus is therapies for melanoma and renal cell carcinoma (RCC), with a particular expertise in targeted therapies... read more »

Jeffrey A. Engelman, MD, PhD

Dr. Engelman is an Associate Professor of Medicine at Harvard Medical School and is the Director of Thoracic Oncology and Director of Molecular Therapeutics at the Mass General Cancer Center. In his role as the Director of Thoracic Oncology, he directs the thoracic oncology team’s research program... read more »

Leif W. Ellisen, MD, PhD

Dr. Leif W. Ellisen is a practicing oncologist and researcher at the MGH Cancer Center, and an Associate Professor of Medicine at Harvard Medical School. He is also co-Executive Director of the Translational Research Laboratory (TRL) for tumor molecular profiling at the MGH Cancer Center. He received his... read more »

A. John lafrate, MD, PhD

Dr. John Iafrate is an Associate Pathologist in the Department of Pathology at MGH and co-Executive Director of the MGH Translational Research Laboratory (TRL), a collaborative effort between the Department of Pathology and the MGH Cancer Center. Through the TRL, Dr. Iafrate does highly complex molecular analyses... read more »

Bruce Chabner, MD

Dr. Bruce Chabner is a Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center. Dr. Chabner graduated summa cum laude from Yale College... read more »

Jeffrey W. Clark, MD

Dr. Clark is a graduate of Massachusetts Institute of Technology, where he graduated Baccalaureate of Science in Biology. He went on to receive his medical degree at Tufts University School of Medicine. His current research efforts involve... read more »

Darrell Borger, PhD

Dr. Darrell Borger is co-director of the Translational Research Laboratory (TRL) at the MGH Cancer Center and an Instructor in Medicine at Harvard Medical School. Dr. Borger co-developed a cutting-edge cancer genotyping approach under... read more »
Find Clinical Trials
The Mass General Cancer Center’s gene-based cancer website can help you access important information about clinical trials that are designed to fight specific cancer mutations, as well as providing critical information regarding these mutations. Use our exclusive My Trial Guide tool to guide you to the best clinical trial and personalized treatment options for you.

Search by Disease, Gene, Mutation, or Drug »

Patient Stories

Greg Vrettos

Athletic. Healthy eater. Non-smoker. At 57, Greg Vrettos' lifestyle profile read like every doctor's recommendation for good health. read more »

Linnea Duff

When Linnea Duff, an active 46-year old mother of three, began experiencing shortness of breath... read more »
Next Steps

Speak with an access nurse today. Our access nurses will help direct you toward the right resources for your needs. Call 877-789-6100
Clinical Trials
The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Learn More »

Contact Us
Please fill out the "Request a Consultation" form or call to get in touch with the MGH Cancer Center today.Ask »

Frequently Asked Questions
Learn more about clinical trials, genomic tests and more.
Explore »